Orforglipron
Orforglipron is an orally administered non-peptide small-molecule GLP-1 receptor agonist, studied for weight management and glycemic control; research protocols typically use 3 mg orally once daily (titrating toward 36 mg).
Best for
It has been studied primarily for chronic weight management in adults with obesity or overweight with weight-related conditions, and for glycemic control in type 2 diabetes, alongside reduced-calorie diet and increased physical activity.
What to expect
Research uses a slow titration over several months, with appetite and weight changes accumulating gradually over the multi-week escalation period rather than appearing immediately.
Pairs with
In research and practice it is typically used on its own as a foundational agent rather than stacked, though trials have studied it relative to or alongside background metabolic therapies such as metformin and SGLT-2 inhibitors in type 2 diabetes.
Research and the approved product use a once-daily oral tablet taken with or without food, with gradual monthly dose escalation from a low starting dose to reduce gastrointestinal effects; founder protocol references roughly 7-14 mg oral daily, which sits within the approved maintenance range.
- How often
- Daily
- Route
- Oral (by mouth)
- Cycle
- 3 → 6 → 12 → 18 → 24 → 36 mg daily, escalate ~every 2–4 weeks if tolerated
The same numbers the goodtides app and the Dose Calc use — a research reference, not a prescription. Responses are individual; research protocols start at the low end.
- Foundayo®ORAL tablet · dailyweight management
Brand names identify the molecule, not the dose. Each brand is a finished prescription product with its own fixed dose steps and its own route — a brand’s milligrams never transfer to a vial.
A swallowed tablet — no vial, no reconstitution, no syringe units. Approved for weight management only, not for type 2 diabetes.
Foundayo is a registered trademark of Eli Lilly and Company. goodtides is not affiliated with, endorsed by, or licensed by Eli Lilly. We sell research-grade orforglipron. We do not sell Foundayo.
Orforglipron is an orally administered, non-peptide small-molecule agonist of the glucagon-like peptide-1 (GLP-1) receptor.
Unlike semaglutide, tirzepatide, and other GLP-1 medicines, which are peptides typically given by injection, orforglipron is a synthetic small molecule, which is the structural basis researchers cite for its oral bioavailability without the food and water restrictions required by oral peptide formulations. It was discovered by Chugai Pharmaceutical and licensed to Eli Lilly.
Research characterizes it as a partial GLP-1 receptor agonist that modulates downstream cAMP signaling to produce GLP-1-like effects, and studies describe activation of the GLP-1 pathway to enhance glucose-dependent insulin secretion, reduce appetite and food intake, and slow gastric emptying. It has been studied extensively in late-stage clinical trials (the ATTAIN and ACHIEVE programs).
As of 2026 it is FDA-approved under the brand name Foundayo for chronic weight management; doses and formulations differ between the approved product and earlier research studies.
- Half-life
- ~24-35 h single-dose (~48-67 h at steady state) — supports once-daily oral dosing
- Peak
- ~2-4 hr post-dose (oral)
- Absorption
- Rapid oral absorption, dose-proportional; minimal food effect — take any time, with or without food
- Bioavailability
- Oral ~30-40%
Log every dose, count every vial, and verify your batches — free in the goodtides app.
This page is educational reference material about compounds studied in research settings. It is not medical advice, and nothing here is a recommendation to buy, possess, or use any compound. Research findings described are from published literature; individual compounds may not be approved for human use. Talk to a licensed clinician about anything that affects your health.